详情页 - 四川省肿瘤医院知识库

当前位置：首页 > 详情页

The clinical utility of CA125/MUC16 in pancreatic cancer: A consensus of diagnostic, prognostic and predictive updates by the Chinese Study Group for Pancreatic Cancer (CSPAC)

134| 认领 | 导出 | 链接全文 |

文献详情

资源类型：

WOS体系：

Pubmed体系：

收录情况： ◇ SCIE

作者：

机构： [1]Department of Pancreatic Surgery, Fudan University Shanghai Cancer Center [2]Department of Oncology, Shanghai Medical College, 3Pancreatic Cancer Institute, Fudan University, Shanghai [4]Department of Pancreaticobiliary Surgery, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, Guangdong [5]Department of Pancreatic Surgery, Pancreatic Disease Institute, Huashan Hospital, Shanghai Medical College, Fudan University, Shanghai [6]Department of Hepatobiliary and Pancreatic Surgery, Zhejiang Provincial People's Hospital, Hangzhou, Zhejiang [7]Department of Pancreatic Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin [8]Department of Pancreatic-Bililary Surgery, Xiangya Hospital, Central South University, Changsha, Hunan [9]Department of Surgery, Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou [10]Department of Hepatobiliary Oncology, Cancer Center, Sun Yat-sen University, Guangzhou, Guangdong [11]Department of Gastroenterological and Pancreatic Surgery, Zhejiang Provincial People's Hospital, Hangzhou [12]Department of Hepatobiliopancreatic Surgery, The People's Hospital of Deyang, Deyang [13]Department of Hepato-Pancreato-Biliary Surgery, The Fourth Hospital of Hebei Medical University, Shijiazhuang [14]Department of Biliary-Pancreatic Surgery, Affiliated Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan [15]Department of Hepato-Pancreato-Biliary Surgery, Peking University Cancer Hospital and Institute, Beijing [16]Department of Pancreatic-Biliary Surgery, Shanghai Changzheng Hospital, Second Military Medical University, Shanghai [17]Department of Pancreatic and Biliary Surgery, The First Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang [18]Department of Biliary-Pancreatic Surgery, Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai [19]Department of Medical Oncology, The First Hospital Affiliated to Soochow University, Suzhou [20]Department of Hepato-Biliary-Pancreatic Surgery, West China Hospital, Sichuan University, Chengdu [21]Department of Medical Oncology, Renji Hospital, School of Medicine, Shanghai Jiaotong University [22]Department of Medical Oncology, Shanghai First People's Hospital [23]Department of Surgery, Huadong Hospital, Fudan University, Shanghai [24]Department of Hepatobiliary and Pancreatic Surgery, First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang [25]Department of Medical Oncology, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai [26]Pancreatic Disease Institute, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei [27]Department of Medical Oncology, Peking University School of Oncolocy, Beijing Institute for Cancer Research, Beijing, P.R. China

出处：

DOI：

ISSN：

关键词： pancreatic cancer cancer antigen 125 mucin 16 diagnosis predictive potency prognosis

摘要：

The prognosis for pancreatic cancer (PC) is poor; however, the timely and accurate treatment of this disease will significantly improve prognosis. Serum biomarkers involve noninvasive tests that facilitate the early detection of tumors, predict outcomes and assess responses to therapy, so that the patient can be continuously monitored and receive the most appropriate therapy. Studies have reported that cancer antigen (CA) 125 [also known as mucin 16 (MUC16)] has functional significance in the tumorigenic, metastatic and drug resistant properties of PC. Our aim was to use this biomarker in the diagnosis, detection of metastasis, prognosis and in the monitoring of the treatment effects of PC. Members of the Chinese Study Group for Pancreatic Cancer (CSPAC) reviewed the literature on CA125/MUC16 and developed an objective consensus on the clinical utility of CA125/MUC16 for PC. They confirmed the role of CA125/MUC16 in tumorigenesis and the progression of PC, and recommended monitoring CA125/MUC16 levels in all aspects of the diagnosis and treatment of PC, particularly those that involve the monitoring of treatments. In addition, they suggested that the combination of other biomarkers and imaging techniques, together with CA125/MUC16, would improve the accuracy of the clinical decision-making process, thereby facilitating the optimization of treatment strategies. Periodic clinical updates of the use of CA125/MUC16 have been established, which are important for further analyses and comparisons of clinical results from affiliates and countries, particularly as regards the in-depth biological function and clinical translational research of this biomarker.

基金：

语种：

被引次数：

WOS：

PubmedID：

中科院(CAS)分区：

出版当年[2016]版：

大类 | 3 区医学

小类 | 3 区肿瘤学

最新[2023]版：

大类 | 3 区医学

小类 | 3 区肿瘤学

JCR分区：

出版当年[2016]版：

Q2 ONCOLOGY

最新[2023]版：

Q1 ONCOLOGY

影响因子： 4.5 最新[2023版] 4.6 最新五年平均 3.079 出版当年[2016版] 3.094 出版当年五年平均 3.018 出版前一年[2015版] 3.333 出版后一年[2017版]

第一作者：

第一作者机构： [1]Department of Pancreatic Surgery, Fudan University Shanghai Cancer Center [2]Department of Oncology, Shanghai Medical College, 3Pancreatic Cancer Institute, Fudan University, Shanghai

通讯机构： [*1]Department of Pancreatic Surgery, Fudan University Shanghai Cancer Center, 270 DongAn Road, Shanghai 200032, P.R. China

推荐引用方式(GB/T 7714)：

APA：

MLA：

The clinical utility of CA125/MUC16 in pancreatic cancer: A consensus of diagnostic, prognostic and predictive updates by the Chinese Study Group for Pancreatic Cancer (CSPAC)

文献详情

相关文献